A clear, evidence-based country-by-country and strain-by-strain comparison of hantavirus case-fatality rates — and what the published cohort numbers actually mean for the 2026 MV Hondius cluster and for travellers into endemic regions.
Hantavirus case-fatality rates vary enormously by strain, by region, and by the maturity of the local critical-care system at the moment the patient arrives. The headline numbers cluster into two very different groups. The New World hantaviruses — Andes virus in Argentina and Chile, Sin Nombre virus in the United States — cause Hantavirus Pulmonary Syndrome (HPS) with published case-fatality rates between 35 and 50 percent. The Old World hantaviruses — Hantaan and Seoul in China and Korea, Puumala in Scandinavia, Dobrava in the Balkans — cause Hemorrhagic Fever with Renal Syndrome (HFRS) with case-fatality rates between under 1 percent and roughly 15 percent depending on strain.
| Country / Region | Primary strain | Syndrome | Published CFR | Annual case load (est.) |
|---|---|---|---|---|
| Argentina | Andes virus | HPS | 35-50% (outbreak setting) | 100-200 cases/yr |
| Chile | Andes virus | HPS | 30-40% | 50-100 cases/yr |
| United States | Sin Nombre virus | HPS | ~36% (CDC HPS Registry) | 20-50 cases/yr |
| Brazil | Multiple New World | HPS | 30-45% | ~100 cases/yr |
| China | Hantaan, Seoul | HFRS | 5-15% (Hantaan), 1-2% (Seoul) | ~10,000 cases/yr |
| South Korea | Hantaan, Seoul | HFRS | 5-10% | ~400 cases/yr |
| Finland / Sweden | Puumala virus | HFRS (mild — Nephropathia Epidemica) | <1% | ~1,000-3,000 cases/yr combined |
| Balkans (Serbia, Bosnia, Slovenia) | Dobrava virus | HFRS | 5-12% | 50-200 cases/yr regionally |
| Germany | Puumala virus | HFRS (mild) | <1% | 100-2,000 cases/yr (variable) |
Three factors dominate the cross-country variation in hantavirus mortality. The first is strain: an Andes virus infection is biologically more lethal than a Puumala virus infection regardless of who the patient is. The second is time-to-care: patients who reach a tertiary intensive care unit with mechanical ventilation and ECMO capacity early in the cardiopulmonary phase have meaningfully better outcomes than the headline case-fatality average. The third is case-counting maturity: countries with strong surveillance count more mild cases in the denominator, which mechanically pulls the CFR down even when the underlying biology has not changed. Finland's sub-1-percent Puumala CFR partly reflects the third factor as well as the first.
The 2026 MV Hondius Andes virus cluster has so far run below the historical Andes virus average. As of Day 13 of the WHO 42-day monitoring window, the cluster sits at 12 cases and 3 deaths — a cluster-level case-fatality rate of approximately 25 percent. The most likely drivers of the below-average CFR are the rapid medical evacuation operation that pulled severe cases to high-volume European and American tertiary centres with ECMO capacity, the early WHO and ECDC coordination, and the comparatively young and healthy passenger cohort of an expedition cruise. WHO and ECDC continue to read the broader cluster as stabilising, with no new PCR-positive results across receiving countries in the past five days.
Case-fatality rates are population averages that do not predict any individual patient's outcome. Two patients with the same age, the same strain, and the same comorbidity profile can have very different outcomes based on time-to-care, baseline cardiopulmonary reserve, and the experience of the receiving centre. The CFR also is not the infection-fatality rate (IFR): mild and subclinical infections almost certainly exist in every endemic region and are not in the denominator of the headline CFR. The true IFR is lower than the CFR in every region listed above, though by how much is genuinely uncertain for the New World hantaviruses where surveillance is dominated by hospitalised cases.
Hantavirus is a low-probability but high-consequence infection. The published mortality numbers by country and strain are real, but they are population averages — and they hide a deeper rule: the single highest-yield intervention available to any patient in any endemic region is the same one the WHO and CDC have stressed throughout the MV Hondius cluster. Know the prodromal symptoms, present urgently if they appear, name the exposure history at triage, and accept rapid escalation to a tertiary ICU at the first sign of respiratory or haemodynamic deterioration.
Andes virus, endemic to Argentina and Chile, carries the highest published case-fatality rate among well-characterised hantaviruses, with outbreak-setting CFRs reported between 35 and 50 percent. Sin Nombre virus in the United States runs close behind at approximately 36 percent per the CDC HPS Registry.
The dominant Scandinavian strain is Puumala virus, which causes the relatively mild Nephropathia Epidemica form of HFRS rather than the more severe HPS. Puumala biology, mature surveillance, and good access to renal supportive care combine to produce a published CFR under 1 percent.
No — it has run below. As of Day 13 of WHO monitoring, the cluster sits at 12 cases and 3 deaths, for a cluster-level CFR of approximately 25 percent. WHO and ECDC continue to read the broader cluster as stabilising.
There is no global hantavirus death registry, but a reasonable estimate based on published surveillance is several hundred deaths per year globally — dominated by HFRS deaths in China at several hundred annually plus tens of HPS deaths in the Americas.